Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 16/20 | 0.53 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | LCK | P06239 | 1/20 | 0.42 |
| ▸ | LYN | P07948 | 1/20 | 0.42 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.42 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.42 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.41 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.41 |
| ▸ | AURKA | O14965 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2745783 | 0.93 | SYK (0.63) | SYKMAOBADORA2AJAK2EGFR | |
| SCHEMBL2103803 | 0.89 | SYK (0.55) | SYKMAOBADORA2AJAK2EGFR | |
| SCHEMBL14607314 | 0.86 | SYK (0.49) | SYKJAK2EGFRLCKLYN | |
| SCHEMBL2745277 | 0.86 | SYK (0.47) | SYKMAOBADORA2AJAK2EGFR | |
| SCHEMBL2745476 | 0.83 | SYK (0.67) | SYKJAK2EGFRLCKLYN | |
| SCHEMBL17278002 | 0.83 | MAOB (0.50) | SYKMAOBADORA2AJAK2EGFR | |
| SCHEMBL2100628 | 0.82 | AURKA (0.57) | SYKMAOBADORA2AJAK2EGFR | |
| SCHEMBL2101544 | 0.81 | SYK (0.61) | SYKMAOBADORA2AJAK2EGFR | |
| SCHEMBL2102368 | 0.81 | SYK (0.61) | SYKMAOBADORA2AJAK2EGFR | |
| SCHEMBL12212798 | 0.81 | SYK (0.49) | SYKMAOBADORA2AJAK2EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178671-B2 | Ring attached at N2 and N4 of 2,4-pyrimidinediamines; for treating rheumatoid arthritis; N4-(2,2-dimethyl-3-oxo-4H-5-pyrid[1,4]oxazin-6-yl)-5-fluoro-N2-(3,4,5-trimethoxyphenyl)-2,4-pyrimidinediamine | RIGEL PHARMACEUTICALS, INC. (US) | 2012-05-15 | — | — | US | claimed |